Harbor Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Harbor Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-96,837	Closed	-$433K	–	727
2024 Q1	$433K	Buy	96,837 +23,327	+32%	+$97.3K	0.06%	433
2023 Q4	$236K	Buy	73,510 +4,991	+7%	+$14.2K	0.05%	341
2023 Q3	$217K	Buy	68,519 +10,473	+18%	+$45.9K	0.05%	347
2023 Q2	$288K	Buy	58,046 +5,288	+10%	+$28.6K	0.06%	324
2023 Q1	$261K	Buy	52,758 +10,957	+26%	+$70.3K	0.08%	193
2022 Q4	$263K	Sell	41,801 -19,493	-32%	-$180K	0.26%	75
2022 Q3	$662K	Sell	61,294 -28,698	-32%	-$390K	0.61%	54
2022 Q2	$1.03M	Sell	89,992 -2,763	-3%	-$24.5K	0.78%	37
2022 Q1	$845K	Sell	92,755 -26,792	-22%	-$279K	0.4%	68
2021 Q4	$1.78M	Buy	+119,547	New	+$2.11M	0.65%	49

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harbor Capital Advisors's ALLO Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 96,837 shares — an estimated $433K sold.

Harbor Capital Advisors first reported a position in ALLO in Q4 2021 and held it in 10 quarters. The position peaked at $1.78M in Q4 2021. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

Harbor Capital Advisors reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
Harbor Capital Advisors sold 96,837 Allogene Therapeutics shares in Q2 2024, an estimated $433K.
Harbor Capital Advisors first reported a position in Allogene Therapeutics in Q4 2021 and held it in 10 quarters.
Harbor Capital Advisors's Allogene Therapeutics position peaked at $1.78M in Q4 2021.
174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.